RxDoctor Payments Data

Omar Ali, MD

Interventional Cardiology · N Chelmsford, MANPI 1881634848

Payments from drug & device makers

$2,171in general payments, 2019–2025

Across 97 payments — averaging $22.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$427
  • AstraZeneca$297
  • Johnson & Johnson$210
  • Pfizer$189
  • Medtronic$138
  • Boston Scientific$133
  • plus $777 from 17 others

What the payments were for

  • Food & beverage$2,171100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,171 in reported general payments places this provider in the 35th percentile of 128 interventional cardiology providers in Massachusetts.

See all interventional cardiology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$193,282
Medicare patients
1,887
Services billed
3,381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UptraviSelexipag13$302,948
EliquisApixaban147$189,586
EntrestoSacubitril/Valsartan26$43,470
XareltoRivaroxaban14$22,036
BrilintaTicagrelor23$20,503
FarxigaDapagliflozin Propanediol22$19,103
JardianceEmpagliflozin18$14,550
Praluent PenAlirocumab11$9,087
Atorvastatin Calcium453$7,623
ClopidogrelClopidogrel Bisulfate427$7,434
Metoprolol Succinate283$6,311
Rosuvastatin Calcium217$5,914
Prasugrel Hcl32$3,187
Ezetimibe79$2,792
Losartan Potassium172$2,319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Uptravi$11$302,94813 claims
PfizerEliquis$189$189,586147 claims
NovartisEntresto$427$43,47026 claims
AstraZenecaBrilinta, Farxiga$297$39,60645 claims
Johnson & JohnsonXarelto$210$22,03614 claims
Boehringer IngelheimJardiance$81$14,55018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 128 interventional cardiology providers in Massachusetts.

Other interventional cardiology in N Chelmsford

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →